HOBOKEN, N.J. (January 25, 2018) - Mountain climber Chris Bombardier of Denver, Colorado on January 6th became the first hemophiliac to climb the Seven Summits of the world with his successful climb of Mount Vinson in Antarctica, a journey made possible with a grant from Octapharma USA. The Seven Summits, the highest peak on each continent, are a feat just over 400 people can claim.
Octapharma USA also sponsored Bombardier's climb in 2017 up Mount Everest, the historic mountain in Nepal. Octapharma's partnership with the mountain climber also includes sponsorship of Bombardier Blood, a documentary scheduled for release later this year that will tell his inspirational story.
"It was incredible to have Octapharma as a partner on this climb as well," said Bombardier. "Climbing the 16,050 feet of Mount Vinson was the last climb in my dream of completing the Seven Summits. I could not have made it without the support of Octapharma, Save One Life and countless others. Together, we have shown the world what can be achieved with the proper support and medical treatment."
Octapharma USA President Flemming Nielsen said that Bombardier's journey has inspired thousands of people around the world.
"Chris has shown all of us that anything is possible if we keep working toward our dreams," said Nielsen. "Everyone at Octapharma congratulates Chris on this incredible accomplishment. It has been an honor for Octapharma to support his mission and we want him to know that our team has been cheering him on with every step of this incredible journey."
"We are so proud of Chris for showing the world what people with Hemophilia are capable of when they have access to medication," said Lynch. "With proper medical care, we can accomplish anything. Believe Limited is grateful to Octapharma for helping to bring this message to people worldwide."
Bombardier Blood highlights the disparity in health care in Nepal using Bombardier's recent Everest summit as a backdrop. Please visit www.bombardierblood.com for more information and a preview of the documentary.
About the Octapharma Group
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation since 1983. Its core business is the development and production of human proteins from human plasma and human cell lines. Octapharma employs approximately 7,100 people worldwide to support the treatment of patients in over 113 countries with products across the following therapeutic areas: Hematology (coagulation disorders), Immunotherapy (immune disorders) and Critical Care. The company's American subsidiary, Octapharma USA, is located in Hoboken, N.J. Octapharma operates two state-of-the-art production sites licensed by the U.S. Food and Drug Administration (FDA), providing a high level of production flexibility. For more information, please visit www.octapharmausa.com.